Clinical trial participation no benefit to pediatric leukemia patients

Can the enrollment in a clinical trial, on its own, be linked to improved outcome for certain cancer patients? In the case of kids with the most common form of pediatric cancer, Acute Lymphoblastic Leukemia (ALL), the answer appears to be a disheartening No.

In a retrospective cohort study of 322 Seattle Children's Hospital patients with newly diagnosed ALL between 1997 and 2005, researchers determined that there was no outcome advantage for those who participated. They reached the rather shifty conclusion that "Discussions about participation in a clinical trial should focus on improvement of future therapy, not the direct benefit of the research participant." Easier said than done when the participant is a child.

The findings were published in the journal Archives of Pediatrics & Adolescent Medicine for March 2010. They were accompanied by a counterpoint editorial written by Dr. Steven Joffe, Framing the Benefits of Cancer Clinical Trials.

By Ross Bonander

Source: No Evidence of a Trial Effect in Newly Diagnosed Pediatric Acute Lymphoblastic Leukemia

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap